Our Firm is representing a number of Xarelto plaintiffs who allegedly experienced dangerous internal bleeding and other complications related to the use of this blood thinner.
New York, New York (PRWEB) February 07, 2015
Xarelto lawsuits (http://www.xareltolawsuit2015.com/) filed on behalf of patients who were allegedly harmed by the blood thinner continue to move forward in the multidistrict litigation underway in U.S. District Court, Eastern District of Louisiana, Bernstein Liebhard LLP reports. According to the Court’s calendar, the litigation’s next monthly Status Conference will be convened on Friday, February 27th, at 9:00 a.m. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Our Firm is representing a number of Xarelto plaintiffs who allegedly experienced dangerous internal bleeding and other complications related to the use of this blood thinner. We are pleased that the federal litigation is progressing, and look forward to the Status Conference later this month,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective devices and drugs including Xarelto. The Firm is currently offering free and confidential case evaluations to individuals who allegedly sustained life-threatening episodes of internal bleeding, strokes, deep vein thrombosis and/or pulmonary embolism caused by Xarelto.
Xarelto was cleared for sale by the U.S. Food & Drug Administration in 2011, and is currently approved to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like all blood thinners, Xarelto can sometimes cause patients to experience internal hemorrhaging. However, no reversal agent has yet been approved to stop Xarelto bleeding.*
The federal Xarelto litigation was established in December 2014 to allow all federally-filed cases alleging injury from the medication to undergo coordinated pretrial proceedings. Court records indicate that nearly 90 claims have been filed in the proceeding on behalf of individuals who allegedly experienced internal bleeding, strokes, deep vein thrombosis, pulmonary embolism and other serious complications related to the use of Xarelto. Among other things, plaintiffs claim the drug's manufacturers wrongly marketed Xarelto as a superior alternative to warfarin, a blood thinner that has been on the market for decades. While there is no antidote to stop Xarelto bleeding, bleeding from warfarin can be stopped via the administration of vitamin K.
Patients who allegedly suffered life-threatening episodes of Xarelto bleeding and other complications may be entitled to compensation for their injury related damages. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP